Brief: Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-Of-Care Profile
28/09/2026 11:35
BRIEF-Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-Of-Care Profile Sept 28 (Reuters) - Kodiak Sciences Inc. KOD.O:
ZENKUDA AND TABIRAFUSP-TED MEET PRIMARY ENDPOINTS IN PIVOTAL DAYBREAK TRIAL IN WAMD, WITH ZENKUDA DEMONSTRATING A POTENTIAL NEW STANDARD-OF-CARE PROFILE WITH STRONG IMMEDIACY AND SUSTAINED CLINICAL EFFECT WITH MAJORITY OF PATIENTS ON 24-WEEK DOSING INTERVAL USING STRICT TREAT-TO-DRYNESS REAL WORLD RETREATMENT CRITERIA.
KODIAK SCIENCES - ZENKUDA BLA PLANNED FOR Q4 2026 TO INCLUDE FIVE POSITIVE PHASE 3 STUDIES
KODIAK SCIENCES INC. - ZENKUDA AND TABIRAFUSP-TED DEMONSTRATED SAFETY CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF AFLIBERCEPT
Source text: ID:nPnjsZr7a
Further company coverage: KOD.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Kodiak Sciences
See all newsBrief: Kodiak Sciences Inc. Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
Ocular Therapeutix tumbles on rival Kodiak's trial win, analyst calls selloff overdone
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX